Global Anti-Inflammatory Cytokines Market By Drug (Interleukin-1, 4, 6, 10, 11, 13), By Route of Administration (Oral, Intravenous), By Indication (Graft Vs Host Disease, Cystic Fibrosis, Cardiovascular Diseases, Adipose Tissue Metabolism and Obesity, Osteoarthritis, Atherosclerosis, Cancer, Infectious Diseases), By End-User (Blood & Blood Products, Biological Samples, Flammable Materials, Drug Hospitals, Specialty Clinics, Research Institutes), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Non-antibody proteins that act as intercellular mediators, and are secreted by inflammatory leukocytes and some non-leukocytic cells. They differ from traditional hormones in that they are produced by a variety of tissue or cell types rather than specific glands. They often function locally, in a paracrine or autocrine rather than endocrine manner.

Cytokines are a wide category of peptides, glycoproteins, and proteins that are found in specific immune system cells. Cytokines are produced in the body by a variety of cells, including lymphocytes, and monocytes, among others. Anti-inflammatory cytokines act as a regulator of cytokine-induced inflammation.

Inflammatory cytokines can cause a cytokine storm, which can lead to nerve damage/inflammation-induced central sensitization, atherosclerosis, or malignancy. According to the National Cancer Institute, more than 1 million cases of cancer are expected to be diagnosed in the United States alone. As a result, the increasing rate of treatment uptake is expected to boost global anti-inflammatory cytokine market growth over the next decade.

Detailed Segmentation –

Based on Drug Type:

• Interleukin-1 Receptor Antagonist
• Interleukin-4
• Interleukin-6
• Interleukin-10
• Interleukin-11
• Interleukin-13

Based on Route of Administration:

• Oral
• Intravenous

Based on Indication:

• Graft-Vs.-Host Disease
• Cystic Fibrosis
• Cardiovascular Diseases
• Adipose Tissue Metabolism and Obesity
• Osteoarthritis
• Atherosclerosis
• Cancer
• Infectious Diseases
• Other Indications

Based on End-User:

• Hospitals
• Specialty Clinics
• Research Institutes

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics –

Drivers for the Global Anti-Inflammatory Cytokines Market:

Rapid advancements in technology have resulted in the emergence of innovative products such as cordless devices, wearables, smartphones, and integrated devices, which in turn have led to the increasing adoption rate of these medical devices. This is another prominent factor responsible for boosting the economic growth of the global anti-inflammatory cytokines market.

Key manufacturers and other medical organizations are also creating active respiration monitoring devices to measure Capnography, respiration rate, pulse oximetry, and pulse rate, are further complementing market growth for the monitoring devices industry.

Furthermore, the incorporation of technologies such as machine learning and signal analysis enhances the growth of portable lung monitors, particularly PSG devices, resulting in the development of the global lung monitoring devices market.

Restraints Global Anti-Inflammatory Cytokines Market:

The global anti-inflammatory cytokines market is projected to be hampered by stringent regulatory criteria for medication approval. Due to weak economic conditions in regions such as the Middle East and Africa, there is a lower rate of diagnosis and treatment adoption, posing a hurdle to the expansion of the worldwide anti-inflammatory cytokines market.

One of the greatest impediments to the growth of the global anti-inflammatory cytokines market in less developed nations is the lack of established healthcare infrastructure. Adverse medication effects will provide a hindrance to the expansion of the worldwide anti-inflammatory cytokines market.

Patent expiration, combined with an increase in generic medicine makers, is predicted to stymie the expansion of the anti-inflammatory cytokine industry.

Opportunities for the Global Anti-Inflammatory Cytokines Market:

The rising number of cancer patients undergoing treatment is expected to boost the expansion of the worldwide anti-inflammatory cytokines market. There has been a substantial increase in understanding of the therapeutic alternatives available for cancer and related illnesses, resulting in growth in the worldwide anti-inflammatory cytokines market.

Changing living habits also contribute to the occurrence of cancer and accelerate the expansion of the anti-inflammatory market. According to the World Health Organization (WHO), there were a total of 19.2 million new cancer cases diagnosed worldwide.

Trends for the Global Anti-Inflammatory Cytokines Market:

Increased investments in healthcare infrastructure and research & development for anti-inflammatory cytokines are projected to drive the worldwide anti-inflammatory cytokines market. The increasing rate of biopharmaceutical drug approval and commercialization will drive worldwide anti-inflammatory cytokine market growth over the next decade.

Changing consumer behavior through the use of cutting-edge technology and a willingness to share data is resulting in the introduction of anti-inflammatory cytokine medications to the market. Because of the high occurrence rate, the cancer indication is predicted to create the most revenue in the global anti-inflammatory cytokines market. During the projected period, the market for anti-inflammatory cytokines is expected to rise due to the expansion of the value chain.

Competitive Landscape –

• Merck KGaA
• Eli Lilly and Company
• Pfizer Inc.
• Sanofi S.A.
• Novartis AG
• Hoffmann-La Roche Ltd.
• Lonza Group Ltd.
• Thermo Fisher Scientific
• Meridian Bioscience Inc.
• General Electric Company
• Abcam PLC
• GenScript Biotech Corp
• Applied Biological Materials Inc.
• Randox Laboratories
• Other Market Players

Recent Development –

• In January 2021, Emergent BioSolutions and Humanigen struck a deal for the research and manufacturing of a medication called Lenzilumab. This medication is intended to prevent and treat cytokine storm-induced immunological hyper-response.
• In January 2021, Tetra Bio-pharma gained FDA approval begin its Phase 1 clinical research with human volunteers for its investigational medicinal medication.
• In July 2020, Derm-Biome Pharmaceutical reported that it had raised $500,000 in pre-seed funding through Pan-Biome Pharmaceutical to develop pharmaceuticals used in the treatment of chronic inflammatory illnesses, including anti-inflammatory cytokines.

For the Anti-Inflammatory Cytokines Market research study, the following years have been considered to estimate the market size: